Neoadjuvant 5-fluorouracil, epirubicinand cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer

Oncology Reports

Volumn 17, Issue 1, 2007, Pages 253-259

  Heller, W ^a   Mazhar, D ^a   Ward, R ^a   Sinnett, H D ^b   Lowdell, C ^a   Phillips, R ^a   Shousha, S ^b   Fayaz, A ^a   Palmieri, C ^a   Coombes, R C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Docetaxel; FEC; Neoadjuvant

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FEC PROTOCOL; FLUOROURACIL; TAXOID;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 34249031260     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30: 96-102, 2001.
2. Von Minckwitz G, Raab G, Caputo A, et al: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676-2685, 2005. (Pubitemid 46179457)
3. Von Minckwitz G, Blohmer JU, Raab G, et al: In vivo chemo-sensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16: 56-63, 2005. (Pubitemid 40124479)
4. Smith IC, Heys SD, Hutcheon AW, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20: 1456-1466, 2002. (Pubitemid 34260523)
5. Diéras V, Fumoleau P, Romieu G, et al: Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 22: 4958-4965, 2004. (Pubitemid 46638621)
6. Bear HD, Anderson S, Brown A, et al: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003. (Pubitemid 46606185)
7. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate and fluorouracil versus fluorouracil, epirubicin and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14: 35-45, 1996.
8. Wils J, Coombes RC, Marty M, et al: Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG). Drugs 45 (Suppl. 2): S46-S50, 1993.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
10. Polychronis A, Sinnett HD, Hadjiminas D, et al: Preoperative gefitinib versus gefitinib and anastrozole in post-menopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6: 383-391, 2005. (Pubitemid 40753744)
11. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003. (Pubitemid 36962641)
12. Schwartz GF, Hortobagyi GN, Masood S, et al: Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, PA, USA. Hum Pathol 35: 781-784, 2004. (Pubitemid 38903069)
13. Evans TR, Yellowlees A, Foster E, et al: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 23: 2988-2995, 2005. (Pubitemid 46224118)
14. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, et al : Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCICSAKK multicenter study. J Clin Oncol 21: 843-850, 2003. (Pubitemid 46606444)
15. Van der Hage JA, van de Velde CJ, Julien JP, et al : Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001. (Pubitemid 33081640)
16. Thomas E, Holmes FA, Smith TL, et al: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer. Long-term results from a prospective randomized trial. J Clin Oncol 22: 2294-2302, 2004. (Pubitemid 41115385)
17. Mouret-Reynier MA, Abrial CJ, Ferrière JP, et al: Neoadjuvant FEC 100 for operable breast cancer: eight-year experience at Centre Jean Perrin. Clin Breast Cancer 5: 303-307, 2004. (Pubitemid 39562118)
18. Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40: 205-211, 2004. (Pubitemid 38077022)
19. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clinic Oncol 19: 602-611, 2001.
20. Deo SV, Bhutani M, Shukla NK, et al: Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol 84: 192-197, 2003. (Pubitemid 37484783)
21. O'Regan RM, von Roenn JH, Carlson RW, et al: Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/ cyclophosphamide) in stage III breast cancer. Clin Breast Cancer 6: 163-168, 2005. (Pubitemid 40975613)
22. Cristofanilli M, Gonzalez-Angulo A, Sneige K, et al: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23: 41-48, 2005. (Pubitemid 41702621)
23. Cocquyt VF, Blondeel PN, Depypere HT, et al: Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29: 361-367, 2003. (Pubitemid 36675693)
24. Pu RT, Schott AF, Sturtz DE, et al: Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol 29: 354-358, 2005. (Pubitemid 40321971)
25. Kuerer HM, Sahin AA, Hunt KK, et al: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230: 72-78, 1999. (Pubitemid 30190367)
26. Amat S, Penault-Llorca F, Cure H, et al: Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncol 20: 791-796, 2002.
27. Burcombe RJ, Makris A, Richman PI, et al: Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155, 2005. (Pubitemid 40188448)
28. Learn PA, Yeh IT, McNutt M, et al: HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer 103: 2252-2260, 2005. (Pubitemid 40686568)
29. Penault-Llorca F, Cayre A, Bouchet Mishellany F, et al: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22: 1319-1325, 2003.
30. Gregory RK, Powles TJ, Salter J, et al: Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 59: 171-175, 2000. (Pubitemid 30216140)
31. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17: 3058-3063, 1999. (Pubitemid 29470633)
32. Schneider J, Lucas R, Sanchez J, et al: Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 20: 4373-4377, 2000.
33. Bottini A, Berruti A, Bersiga A, et al: Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16: 3105-3110, 1996. (Pubitemid 26390257)
34. Taucher S, Rudas M, Gnant M, et al: Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10: 91-98, 2003. (Pubitemid 36457240)
35. Aas T, Geisler S, Helle H, et al: Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncol Rep 13: 525-530, 2005.
36. Scholl SM, Fourquet A, Asselain B, et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A: 645-652, 1994. (Pubitemid 24164252)
37. Buzdar AU, Ibrahim NK, Francis D, et al: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.